Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 10/20 | 0.46 |
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 5/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2501544 | 0.84 | ALDH1A1 (0.47) | LMNAALDH1A1CYP3A4MAPTMEN1 | |
| SCHEMBL9363333 | 0.83 | ALDH1A1 (0.47) | LMNAALDH1A1CYP3A4MAPTMEN1 | |
| SCHEMBL24227146 | 0.83 | ALDH1A1 (0.42) | LMNAALDH1A1CYP3A4MAPTMEN1 | |
| SCHEMBL12889912 | 0.82 | TERT (0.47) | LMNAALDH1A1CYP3A4MAPTMEN1 | |
| SCHEMBL13296552 | 0.81 | ALDH1A1 (0.47) | LMNAALDH1A1CYP3A4MAPTMEN1 | |
| SCHEMBL10020928 | 0.80 | ALDH1A1 (0.49) | LMNAALDH1A1CYP3A4MAPTMEN1 | |
| SCHEMBL5377820 | 0.80 | ALDH1A1 (0.42) | LMNAALDH1A1CYP3A4MAPTMEN1 | |
| SCHEMBL12781700 | 0.79 | S100B (0.56) | LMNAALDH1A1CYP3A4MAPTMEN1 | |
| SCHEMBL13122705 | 0.79 | AR (0.46) | ALDH1A1CYP3A4MEN1KMT2AKDM4E | |
| SCHEMBL15934249 | 0.79 | LMNA (0.55) | LMNATRPA1CHRM1SLC6A2ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236082-B2 | EZH2 inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20200338074-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-10702527-B2 | Combination therapy of transcription inhibitors and kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190192532-A1 | COMBINATION THERAPY OF BROMODOMAIN INHIBITORS AND CHECKPOINT BLOCKADE | PETER MACCALLUM CANCER INSTITUTE (AU) | 2019-06-27 | — | — | US | disclosed |
| US-10308653-B2 | Diazepane derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20190015411-A9 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20190000860-A1 | USE OF COMPOSITIONS MODULATING CHROMATIN STRUCTURE FOR GRAFT VERSUS HOST DISEASE (GVHD) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-01-03 | — | — | US | disclosed |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-9951074-B2 | Dihydropteridinone derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170145023-A1 | DIAZEPANE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145013-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145013-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-9540317-B2 | Class- and isoform-specific HDAC inhibitors and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-01-10 | — | — | US | disclosed |
| US-20150307444-A1 | CLASS- AND ISOFORM-SPECIFIC HDAC INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-10-29 | — | — | US | disclosed |
| US-8716344-B2 | Class- and isoform-specific HDAC inhibitors and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-05-06 | — | — | US | disclosed |
| US-20120208889-A1 | CLASS- AND ISOFORM-SPECIFIC HDAC INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUE, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-8193168-B2 | Use of a TRPM5 inhibitor to regulate insulin and GLP-1 release | REDPOINT BIO CORPORATION (US) | 2012-06-05 | — | — | US | disclosed |
| US-20080306030-A1 | Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release | REDPOINT BIO CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| US-20070207093-A1 | Hydrazone derivatives and uses thereof | LINQUAGEN CORP. | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190000860-A1 | USE OF COMPOSITIONS MODULATING CHROMATIN STRUCTURE FOR GRAFT VERSUS HOST DISEASE (GVHD) | BCL6, BCL6B, EZH2 | LMNA 4192/4885TRPA1 4872/4885CHRM1 4622/4885 |
| US-10308653-B2 | Diazepane derivatives and uses thereof | BRDT, BRD4, BAZ2A | LMNA 744/4885TRPA1 4635/4885CHRM1 1714/4885 |
| US-10702527-B2 | Combination therapy of transcription inhibitors and kinase inhibitors | CHUK, BCOR, MYC | LMNA 2211/4885TRPA1 4828/4885CHRM1 4859/4885 |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | LMNA 2211/4885TRPA1 4828/4885CHRM1 4859/4885 |
| US-20150307444-A1 | CLASS- AND ISOFORM-SPECIFIC HDAC INHIBITORS AND USES THEREOF | HDAC1, HDAC5, HDAC6 | LMNA 1808/4885TRPA1 3003/4885CHRM1 4771/4885 |
| US-20070207093-A1 | Hydrazone derivatives and uses thereof | TAS2R1, TAS2R5, TAS1R1 | LMNA 4648/4885TRPA1 31/4885CHRM1 115/4885 |
| US-20190015411-A9 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | LMNA 2211/4885TRPA1 4828/4885CHRM1 4859/4885 |
| US-20120208889-A1 | CLASS- AND ISOFORM-SPECIFIC HDAC INHIBITORS AND USES THEREOF | HDAC1, HDAC5, HDAC6 | LMNA 1808/4885TRPA1 3003/4885CHRM1 4771/4885 |
| US-20190192532-A1 | COMBINATION THERAPY OF BROMODOMAIN INHIBITORS AND CHECKPOINT BLOCKADE | BRD4, BRD3, BRPF3 | LMNA 4249/4885TRPA1 4008/4885CHRM1 3664/4885 |
| US-20170145013-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | BRDT, BRD4, BRD3 | LMNA 753/4885TRPA1 4682/4885CHRM1 3318/4885 |
| US-20080306030-A1 | Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release | GLP1R, GIPR, TRPM5 | LMNA 3506/4885TRPA1 67/4885CHRM1 1970/4885 |
| US-11236082-B2 | EZH2 inhibitors and uses thereof | EZH2, EZH1, BMI1 | LMNA 2203/4885TRPA1 4884/4885CHRM1 4763/4885 |
| US-20200338074-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | LMNA 2211/4885TRPA1 4828/4885CHRM1 4859/4885 |
| US-20170145023-A1 | DIAZEPANE DERIVATIVES AND USES THEREOF | BRDT, BRD4, BAZ2A | LMNA 744/4885TRPA1 4635/4885CHRM1 1714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.